PSORIASIS AND CARDIOVASCULAR DISEASE: IS IT CORRELATE?

Sidhi Laksono; Wincent Candra

doi:10.32502/sm.v12i2.3935

PSORIASIS AND CARDIOVASCULAR DISEASE: IS IT CORRELATE?

Sidhi Laksono, Wincent Candra

Abstract

Psoriasis is a common chronic inflammatory disease. This disease can cause a significant reduction in a person's quality of life. Systemic inflammation of psoriasis is thought to play a role in increasing the incidence of cardiovascular disease. Cardiovascular disease in psoriasis patients is a significant economic burden. Therefore, it is important for a doctor to understand and prevent the occurrence of cardiovascular disease in this population. This review aims to review the relationship between psoriasis and the incidence of cardiovascular disease, the underlying mechanisms, and the impact of the treatment of each disease on the other. There are overlapping risk factors for these two conditions. The underlying pathology of these two diseases is inflammation. The inflammation and treatment of one of these diseases might have an impact on the other. Psoriasis and cardiovascular disease are closely related to each other.

Keywords

cardiovascular disease, psoriasis, treatment

Full Text:

PDF (Bahasa Indonesia) PDF (Bahasa Indonesia)

References

Augustin M & Radtke MA. 2014. Quality of life in psoriasis patients. Expert Rev Pharmacoecon Outcomes Res. 14:559–568.

Hu SC-S & Lan C-CE. 2017. Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment. Int J Mol Sci. 18:2211.

Furue M, Tsuji G, Chiba T & Kadono T. 2017. Cardiovascular and Metabolic Diseases Comorbid with Psoriasis: Beyond the Skin. Intern Med. 56:1613–1619.

Takeshita J, Grewal S, Langan SM, et al. 2017. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 76:377–390.

Ma L, Li M, Wang H, Li Y & Bai B. 2014. High prevalence of cardiovascular risk factors in patients with moderate or severe psoriasis in northern China. Arch Dermatol Res. 306:247–251.

Shah K, Mellars L, Changolkar A & Feldman SR. 2017. Real-world burden of comorbidities in US patients with psoriasis. J Am Acad Dermatol. 77:287-292.e4.

Puig L. 2017. Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis. Int J Mol Sci. 19:E58.

Augustin M, Vietri J, Tian H & Gilloteau I. 2017. Incremental burden of cardiovascular comorbidity and psoriatic arthritis among adults with moderate-to-severe psoriasis in five European countries. J Eur Acad Dermatol Venereol. 31:1316–1323.

Feldman SR, Tian H, Gilloteau I, Mollon P & Shu M. 2017. Economic burden of comorbidities in psoriasis patients in the United States: results from a retrospective U.S. database. BMC Health Serv Res. 17:337.

Holm JG & Thomsen SF. 2019. Type 2 diabetes and psoriasis: links and risks. Psoriasis (Auckl). 9:1–6.

Wang H, Wang Z, Rani PL, et al. 2017. Identification of PTPN22, ST6GAL1 and JAZF1 as psoriasis risk genes demonstrates shared pathogenesis between psoriasis and diabetes. Exp Dermatol. 26:1112–1117.

Faurschou A, Pedersen J, Gyldenløve M, et al. 2013. Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques. Exp Dermatol. 22:150–152.

Gyldenløve M, Vilsbøll T, Zachariae C, et al. 2015. Impaired incretin effect is an early sign of glucose dysmetabolism in nondiabetic patients with psoriasis. J Intern Med. 278:660–670.

Naldi L. 2016. Psoriasis and smoking: links and risks. Psoriasis (Auckl). 6:65–71.

Armstrong AW, Harskamp CT, Dhillon JS & Armstrong EJ. 2014. Psoriasis and smoking: a systematic review and meta-analysis. Br J Dermatol. 170:304–314.

Masson W, Lobo M & Molinero G. 2020. Psoriasis and Cardiovascular Risk: A Comprehensive Review. Adv Ther. 37:2017–2033.

Zeng J, Luo S, Huang Y & Lu Q. 2017. Critical role of environmental factors in the pathogenesis of psoriasis. J Dermatol. 44:863–872.

Højgaard P, Glintborg B, Hetland ML, et al. 2015. Association between tobacco smoking and response to tumour necrosis factor ? inhibitor treatment in psoriatic arthritis: results from the DANBIO registry. Ann Rheum Dis. 74:2130–2136.

Di Lernia V, Ricci C, Lallas A & Ficarelli E. 2014. Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers: a retrospective study. J Dermatolog Treat. 25:73–74.

Choudhary S, Pradhan D, Pandey A, et al. 2020. The Association of Metabolic Syndrome and Psoriasis: A Systematic Review and Meta-Analysis of Observational Study. Endocr Metab Immune Disord Drug Targets. 20:703–717.

Mottillo S, Filion KB, Genest J, et al. 2010. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 56:1113–1132.

Zwain A, Aldiwani M & Taqi H. 2021. The Association Between Psoriasis and Cardiovascular Diseases. Eur Cardiol. 16:e19.

Eder L, Chandran V & Gladman DD. 2014. The Framingham Risk Score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease. Ann Rheum Dis. 73:1990–1996.

Fernández-Torres R, Pita-Fernández S & Fonseca E. 2013. Psoriasis and cardiovascular risk. Assessment by different cardiovascular risk scores. J Eur Acad Dermatol Venereol. 27:1566–1570.

Agca R, Heslinga SC, Rollefstad S, et al. 2017. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 76:17–28.

Piepoli MF, Hoes AW, Agewall S, et al. 2016. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 37:2315–2381.

Amaya-Amaya J, Montoya-Sánchez L & Rojas-Villarraga A. 2014. Cardiovascular Involvement in Autoimmune Diseases. Biomed Res Int. 2014:367359.

Shaharyar S, Warraich H, McEvoy JW, et al. 2014. Subclinical cardiovascular disease in plaque psoriasis: association or causal link? Atherosclerosis. 232:72–78.

Lucke M, Messner W, Kim ESH & Husni ME. 2016. The impact of identifying carotid plaque on addressing cardiovascular risk in psoriatic arthritis. Arthritis Res Ther. 18:178.

Kaiser H, Abdulla J, Henningsen KMA, Skov L & Hansen PR. 2019. Coronary Artery Disease Assessed by Computed Tomography in Patients with Psoriasis: A Systematic Review and Meta-Analysis. Dermatology. 235:478–487.

Elloso MM, Gomez-Angelats M & Fourie AM. 2012. Targeting the Th17 pathway in psoriasis. J Leukoc Biol. 92:1187–1197.

Coumbe AG, Pritzker MR & Duprez DA. 2014. Cardiovascular Risk and Psoriasis: Beyond the Traditional Risk Factors. The American Journal of Medicine. 127:12–18.

Sorokin AV, Kotani K, Elnabawi YA, et al. 2018. Association Between Oxidation-Modified Lipoproteins and Coronary Plaque in Psoriasis. Circ Res. 123:1244–1254.

Jialal I & Remaley AT. 2014. Measurement of low-density lipoprotein cholesterol in assessment and management of cardiovascular disease risk. Clin Pharmacol Ther. 96:20–22.

Liu X, Gorzelanny C & Schneider SW. 2019. Platelets in Skin Autoimmune Diseases. Front Immunol. 10:1453.

Fan Z, Wang L, Jiang H, Lin Y & Wang Z. 2021. Platelet Dysfunction and Its Role in the Pathogenesis of Psoriasis. Dermatology. 237:56–65.

Socha M, Pietrzak A, Grywalska E, et al. 2019. The effect of statins on psoriasis severity: a meta-analysis of randomized clinical trials. Arch Med Sci. 16:1–7.

Wu S, Han J, Li W-Q & Qureshi AA. 2014. Hypertension, antihypertensive medication use, and risk of psoriasis. JAMA Dermatol. 150:957–963.

Baccino D, Merlo G, Cozzani E, et al. 2020. Cutaneous effects of antihypertensive drugs. G Ital Dermatol Venereol. 155:202–211.

Ip W & Kirchhof MG. 2017. Glycemic Control in the Treatment of Psoriasis. Dermatology. 233:23–29.

Wu C-Y, Shieh J-J, Shen J-L, et al. 2015. Association between antidiabetic drugs and psoriasis risk in diabetic patients: results from a nationwide nested case-control study in Taiwan. J Am Acad Dermatol. 72:123–130.

Singh S & Bhansali A. 2016. Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort). BMC Dermatol. 16:12.

Kim SC, Schneeweiss S, Glynn RJ, et al. 2015. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study. Ann Rheum Dis. 74:1968–1975.

Hafez VG, Bosseila M, Abdel Halim MRE, et al. 2015. Clinical effects of “pioglitazone”, an insulin sensitizing drug, on psoriasis vulgaris and its co-morbidities, a double blinded randomized controlled trialx1. J Dermatolog Treat. 26:208–214.

Sakaeda T, Kobuchi S, Yoshioka R, et al. 2018. Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors. Int J Med Sci. 15:937–943.

DOI: https://doi.org/10.32502/sm.v12i2.3935